Two cases of ipecac myopathy, one with associated cardiomyopathy are reported. Both patients were young women with eating disorders who came to medical attention because of diffuse muscle weakness. Clinical and electromyographic data suggested ipecac myopathy and muscle biopsies confirmed this diagnosis. One patient had associated clinical and echocardiographic evidence of significant cardiomyopathy. The myopathy resolved and the echocardiogram returned to normal after discontinuing the use of ipecac.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1015020 | PMC |
| http://dx.doi.org/10.1136/jnnp.56.5.560 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A study of intragastric and intravesicular pressure changes during rest, coughing, weight lifting, retching, and vomiting.
Surg Endosc
December 2008
Department of Surgery, University of Missouri Columbia, One Hospital Drive, Columbia, MO 65212, USA.
Background: In patients undergoing a variety of procedures, surgical success is in part dependent on maintaining normal intra-abdominal pressure in the immediate postoperative period. Our objective was to quantify intragastric and intravesicular pressures during activities, through the use of manometry catheters.
Methods: Ten healthy volunteers had a manometry catheter placed transnasally, and a urinary Foley catheter placed.
Medically unexplained myopathy due to ipecac abuse.
Psychosomatics
March 2006
Department of Psychiatry, Georgetown University, Washington, DC, USA.
The use of ipecac, once recommended as an emetic for use in toxic ingestions, has more recently been discouraged for use in home and emergency room settings. It remains readily available, and has been associated with abuse in eating disorders and Munchausen syndrome by proxy. This case discusses an adolescent boy who surreptitiously abused ipecac in the context of distress over parental conflict, and the extensive medical workup undertaken to evaluate unexplained symptoms of proximal muscle weakness, abdominal pain, and, eventually, cardiomyopathy that are sequelae of ipecac toxicity.
View Article and Find Full Text PDFCase of the month. June 1996--anorexia nervosa.
Brain Pathol
October 1996
Department of Neurology, University of Pittsburgh, USA.
A 32 year old woman with a history of anorexia nervosa began experiencing severe muscle weakness. Proximal weakness was worse than distal and she became unable to walk. Serum creatine kinase was elevated 15-fold and EMG was consistent with a myopathic process.
View Article and Find Full Text PDFEmetine myopathy in a patient with an eating disorder.
Med J Aust
January 1994
Department of Neurology, Alfred Hospital, Prahran, Vic.
Objective: To alert physicians to the dangers of a readily available, non-prescription drug by describing the clinical and pathological features of myopathy due to chronic poisoning with ipecac syrup in a patient with an eating disorder.
Clinical Features: A 27-year-old woman presented in 1991 with a right foot drop, followed a few months later by progressive severe neck and limb weakness associated with dysphagia, faecal incontinence and diffuse body ache. It emerged that she had been consuming increasing quantities of ipecac syrup (up to 200 mL per week) for three months to induce vomiting and weight loss.
Ipecac myopathy and cardiomyopathy.
J Neurol Neurosurg Psychiatry
May 1993
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Two cases of ipecac myopathy, one with associated cardiomyopathy are reported. Both patients were young women with eating disorders who came to medical attention because of diffuse muscle weakness. Clinical and electromyographic data suggested ipecac myopathy and muscle biopsies confirmed this diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!